^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hepavac (IMA970A)

    i
    Other names: IMA970A, IMA 970A, HepaVac-101 vaccine, IMA 970 A
    Associations

    News

    Trials
    Company:
    CureVac, Immatics
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    8ms
    A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) (clinicaltrials.gov)
    P1, N=10, Recruiting, National Cancer Institute, Naples | Trial completion date: Jan 2024 --> Nov 2026 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    Imfinzi (durvalumab) • Hepavac (IMA970A)
    10ms
    A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) (clinicaltrials.gov)
    P1, N=10, Recruiting, National Cancer Institute, Naples
    New P1 trial • Combination therapy • IO biomarker
    |
    Imfinzi (durvalumab) • Hepavac (IMA970A)
    over2years
    Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. (PubMed, Clin Cancer Res)
    Immunotherapy may provide a great improvement in treatment options for HCC. HepaVac-101 is a first-in-man clinical vaccine trial with multiple novel HLA class I- and class II-restricted TAAs against HCC. The results are initial evidence for safety and immunogenicity of the vaccine. Further clinical evaluations are warranted.
    P1/2 data • Clinical Trial,Phase II • Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • TLR7 (Toll Like Receptor 7)
    |
    HLA-A*02
    |
    cyclophosphamide • CV8102 • Hepavac (IMA970A)